<DOC>
	<DOC>NCT01970098</DOC>
	<brief_summary>The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.</brief_summary>
	<brief_title>A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<criteria>Japanese SCD patients with mild to moderate ataxia Patients with secondary ataxia Patients with clinically significant hepatic, renal, or cardiovascular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Spinocerebellar degeneration (SCD)</keyword>
	<keyword>Thyrotropin-Releasing Hormone (TRH)</keyword>
	<keyword>Spinocerebellar Ataxia (SCA)</keyword>
	<keyword>Cortical Cerebellar Atrophy (CCA)</keyword>
</DOC>